TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00001436
Drug: OncoLAR® (Registered Trademark)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05871489
Drug: Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed
Study: NCT05871489
Drug: Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed
Study: NCT02411253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
Study: NCT01037699
Drug: rFSH: Follicle Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002792
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002792
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03708744
Drug: A: M207 3.8mg, 30 min, upper arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
Study: NCT03708744
Drug: B: M207 3.8 mg, 30 min, thigh
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
Study: NCT03708744
Drug: C: M207 3.8 mg, 1 hr, upper arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
Study: NCT00610194
Drug: RDEA119
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
Study: NCT01050699
Drug: Midazolam and Fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)
Study: NCT02648659
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500mg 1tablet bid(2times/day)
Study: NCT00101062
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02475499
Drug: Sulfonylureas
Normalized name: Sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study: NCT02475499
Drug: Thiazolidinediones
Normalized name: Thiazolidinediones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study: NCT02475499
Drug: Alpha-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
Study: NCT04609579
Drug: SNX281
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter of each 21-day cycle for up to 6 cycles, or until disease progression or unacceptable toxicity occurs. Cycle 1 length varies from 21 days in monotherapy arm to 28 days in the combination arm.
Study: NCT01385683
Drug: Dabigatran then dabigatran and clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
Study: NCT01385683
Drug: Clarithromycin and dabigatran then dabigatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
Study: NCT00913562
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet rosuvastatin 10 mg per day for 12 weeks
Study: NCT00913562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet a day for 12 weeks
Study: NCT02137928
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
Study: NCT04303598
Drug: FNC placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet，QD
Study: NCT02819271
Drug: CXL-1427 Descending Dose
Normalized name: Defend II
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02526199
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant to perinerual block
Study: NCT03937596
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo during the blinded phase (10 days).
Study: NCT00004311
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00805519
Drug: Glucosamine and chondroitin sulfate
Normalized name: Glucosamine and Chondroitin Sulfate Sodium Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
Study: NCT00805519
Drug: glucosamine and chondroitin sulfate plus Prednisolone
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
Study: NCT00805519
Drug: Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
Study: NCT03810235
Drug: Transdermal Hydrocolloid Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocolloid placebo patches
Study: NCT03856645
Drug: OKG-0301
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
Study: NCT02606617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
Study: NCT01349699
Drug: endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
Study: NCT01349699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol.
Study: NCT02372942
Drug: Lattoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 515 pregnant women using lattoferrin to prevent preterm delivery
Study: NCT03071874
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2014 is a dual mTORC1/mTORC2 inhibitor
Study: NCT02418819
Drug: PF-06412562 3mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562
Study: NCT02418819
Drug: PF-06412562 9mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562
Study: NCT02418819
Drug: PF-06412562 45mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06412562
Study: NCT00782353
Drug: ANA598 400 mg bid or placebo
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANA598 400 mg bid or placebo
Study: NCT03530345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass vials with matching placebo.
Study: NCT00586430
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo
Study: NCT03813602
Drug: Cannabis Sativa
Normalized name: CANNABIS SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg cannabis cigarette with 12.5% THC
Study: NCT03216915
Drug: Gilenya®; Novartis Pharmaceuticals Corporation
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
Study: NCT01786551
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg daily for 14 days
Study: NCT02173756
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
Study: NCT03669965
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRT-232, administered by mouth
Study: NCT00315042
Drug: Telithromycin (HMR3647)
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02005627
Drug: Grazax
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
Study: NCT00744406
Drug: Antidepressant medication (sertraline ,paroxetineor or venlafaxine)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Study: NCT01589809
Drug: nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose-escalation, 2-8 grams, oral
Study: NCT01550107
Drug: Lactose tablets
Normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo tablets b.d
Study: NCT02534129
Drug: Difinsa53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difinsa53 cream is applied to one half of radiation field
Study: NCT00640185
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take up to two 40 mg tablets once daily for 8 weeks.
Study: NCT00640185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take one or two placebos once daily for the duration of the study.
Study: NCT01755247
Drug: 8% NVN1000 Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01755247
Drug: 8% NVN1000 Topical Gel and moisturizer
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo
Study: NCT04599855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be self administered as nasal spray.
Study: NCT03887429
Drug: SXC-2023
Approvals — FDA: no, EMA: no, PMDA: no
Description: SXC-2023 oral capsules
Study: NCT03887429
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo oral capsules
Study: NCT01544192
Drug: Gingko Biloba
Normalized name: Gingko Biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
Study: NCT01544192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group did not receive oral neuroprotective agent
Study: NCT01544192
Drug: Antioxidant formula
Normalized name: Antioxidant Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x1 tablet AOF
Study: NCT00606346
Drug: No Biologics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments will be prescribed according to investigator judgement.
Study: NCT00694720
Drug: AVE0657
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules once a day at bedtime
Study: NCT00694720
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules once a day at bedtime
Study: NCT01869569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
Study: NCT00195494
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 \& 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2
Study: NCT00195494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Study: NCT00819572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00513357
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg by mouth daily for 4 Weeks
Study: NCT00513357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule by mouth daily for 4 Weeks
Study: NCT04568304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
Study: NCT02762500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01350102
Drug: AmeriGel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
Study: NCT00092378
Drug: MK0966, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092378
Drug: Comparator: diclofenac sodium, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01316809
Drug: AZD8055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will start at 120 mg once daily
Study: NCT01748578
Drug: EBI-005-1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
Study: NCT01748578
Drug: EBI-005-1 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04165096
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO
Study: NCT02640807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administration of Placebo (SC administration for patients with INR\>2.5 or platelet count \< 35,000
Study: NCT00515112
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00144235
Drug: Pharmaton PHL 00749
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00144235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02322372
Drug: Femoral blockade
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
Study: NCT02322372
Drug: Intrathecal anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with heavy bupivacaine
Study: NCT02767999
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg of fluoxetine capsule per day from D0 to D90
Study: NCT02767999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: cellulose placebo per day from D0 to D90
Study: NCT01435499
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
Study: NCT01001806
Drug: Ketorolac Tromethamine 0.45%
Normalized name: KETOROLAC TROMETHAMINE 0.45%PF OPH 0.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
Study: NCT00443755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
Study: NCT03533803
Drug: Indomethacin 100Mg Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
Study: NCT01001806
Drug: bromfenac 0.09%
Normalized name: Bromfenac 0.09% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: One day pre operative 1 drop BID then 3 doses pre op day of surgery
Study: NCT01001806
Drug: nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop BID, 1 day pre operative and then 3 doses the day of surgery
Study: NCT00045591
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg PO bid
Study: NCT00045591
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg PO bid
Study: NCT04234594
Drug: Vectibix®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg intravenous (IV) infusion only once，on the first day.
Study: NCT00185783
Drug: Hydrocortisone Administration (Standard of Care Therapy)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01055470
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
Study: NCT01055470
Drug: Lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
Study: NCT00003394
Drug: endocrine-modulating drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02603107
Drug: DRV
Normalized name: Urinal Male Drv RTLPC23201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tablet administered orally once daily with food
Study: NCT02603107
Drug: ATV/co
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300/150 mg FDC tablet administered orally once daily with food
Study: NCT02603107
Drug: DRV/co
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800/150 mg FDC tablet administered orally once daily with food
Study: NCT02603107
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg FDC tablet administered orally once daily without regard to food
Study: NCT02603107
Drug: ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/300 mg tablet administered orally once daily with or without regard to food
Study: NCT02603107
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food
Study: NCT00019630
Drug: doxorubicin HCl liposome
Normalized name: DOXORUBICIN HCL LIPOSOME 2MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01862614
Drug: Articaine Hydrochloride + Epinephrine
Normalized name: articaine hydrochloride / epinephrine Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01862614
Drug: Buffered Articaine Hydrochloride + Epinephrine
Normalized name: articaine hydrochloride / epinephrine Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02454868
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil for intubation without neuromuscular blockade
Study: NCT04622072
Drug: XZP-5809-TT1 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single tartrate of XZP-5809
Study: NCT01621321
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
Study: NCT04967859
Drug: 0.1% gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient using 0.1% gentamicin ointment at the exit site of the hemodialysis catheter
Study: NCT04967859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients using placebo ointment at the exit site of the hemodialysis catheter
Study: NCT00038311
Drug: PN-152,243)/PN-196,444
Approvals — FDA: no, EMA: no, PMDA: no